First, the de novo expression of NCRs (NKp30 in particular) endows circulating Vδ1 T cells with potent cytolytic ability against primary leukemia cells resistant to the lysis exerted by the more abundant Vγ9Vδ2 cell subset (Correia et al., 2011), which have been the focus of essentially all γδ T cell-based cancer immunotherapy trials. Here, NCR3 is linked to leukemia.